Inspire Medical Systems, Inc. Announces Cigna Coverage for Inspire Therapy for the Treatment of Obstructive Sleep Apnea

Download as PDF

MINNEAPOLIS, Minnesota – June 16, 2020 – Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical
technology company focused on the development and commercialization of innovative and minimally invasive
solutions for patients with obstructive sleep apnea (“OSA”), announced today that Cigna, one of the leading health
plans in the United States, will provide coverage for the Company’s Inspire therapy, effective June 15, 2020. Cigna
Corporation is a global health service company that provides health insurance coverage for approximately 16 million
members in the U.S.

“We are very pleased to receive this positive coverage decision from Cigna. As health plans continue to update
their coverage policies to include Inspire therapy, an increasing number of patients and physicians will have access
to our innovative therapy,” said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems.
“With the addition of Cigna, we now have 54 coverage policies, representing over 180 million members, that cover
Inspire therapy, compared to 83 million members just one year ago.”

In addition to the 54 commercial coverage policies, Inspire therapy will soon have Medicare coverage across the
entire United States. The final Medicare Administrative Contractor (“MAC”), Palmetto GBA, LLC (“Palmetto”),
announced its final Local Coverage Decision (“LCD”) policy date release of June 21, 2020, for covering Inspire

“Importantly, the Cigna policy and all of the Medicare LCD policies became, or will become, effective during the
COVD-19 pandemic, and we anticipate that these collective policies position us well to further accelerate growth
once the impact of COVID-19 subsides,” concluded Mr. Herbert.

Under its policy, Cigna considers Inspire’s U.S. Food and Drug Administration (“FDA”) approved hypoglossal nerve
neurostimulation device to be medically necessary for the treatment of moderate to severe OSA when specified
criteria are met, including a previous attempt at continuous positive airway pressure (“CPAP”) treatment.

About Inspire Medical Systems

Inspire is a medical technology company focused on the development and commercialization of innovative and
minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first
and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to
severe obstructive sleep apnea.

For additional information about Inspire, please visit

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements,
including, without limitation, statements regarding the expected growth in our business following the impact of
COVID-19, the release date of the Palmetto final LCD and improvements in market access. In some cases, you
can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’
‘‘could,’’ “future,” “outlook,” “guidance,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’
‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or other similar expressions, although not all forward-looking
statements contain these words.

These forward-looking statements are based on management’s current expectations and involve known and
unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, estimates regarding the annual total addressable
market for our Inspire therapy in the U.S. and our market opportunity outside the U.S.; future results of operations,
financial position, research and development costs, capital requirements and our needs for additional financing;
commercial success and market acceptance of our Inspire therapy; the impact of the ongoing and global COVID-19
pandemic; and general and international economic, political, and other risks, including currency and stock market
fluctuations and the uncertain economic environment. Other important factors that could cause actual results,
performance or achievements to differ materially from those contemplated in this press release can be found under
the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of
Operations“ in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as updated in our
Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and as such factors may be updated from
time to time in our other filings with the SEC, which are accessible on the SEC’s website at and the
Investors page of our website at These and other important factors could cause actual
results to differ materially from those indicated by the forward-looking statements made in this press release. Any
such forward-looking statements represent management’s estimates as of the date of this press release. While we
may elect to update such forward-looking statements at some point in the future, unless required by applicable law,
we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not
assume that our silence over time means that actual events are bearing out as expressed or implied in such
forward-looking statements. These forward-looking statements should not be relied upon as representing our views
as of any date subsequent to the date of this press release.

Investor & Media Contact:
Bob Yedid
LifeSci Advisors
[email protected]